Table 3.
Treatment-emergent adverese events (TEAEs)
| TEAE (MedDRA preferred term) | Group A (L-Arginine) | Group B (tadalafil) | Group C (L arginine + tadalafil) | P value (chi-square test) |
|---|---|---|---|---|
| Headache | 2 | 8 | 11 | |
| Nasal congestion | 0 | 5 | 6 | |
| Back pain | 0 | 7 | 6 | |
| Dyspepsia | 2 | 11 | 14 | |
| Influenza | 0 | 2 | 1 | |
| Myalgia | 0 | 8 | 9 | |
| Upper respiratory tract infection | 0 | 1 | 0 | |
| Sinusitis | 0 | 1 | 0 | |
| Bronchitis | 0 | 1 | 0 | |
| Cough | 0 | 1 | 2 | |
| Insomnia | 5 | 0 | 7 | |
| flushing | 2 | 5 | 7 | |
| Dizziness | 0 | 3 | 4 | |
| TOTAL OF ADVERSE EVENTS REPORTED | 11 | 53 | 67 | <.0001 |
MedDRA = Medical Dictionary for Regulatory Activities.